van Putten M, et al. - Researchers examined the use of perioperative treatment in patients diagnosed with potentially resectable gastric cancer (cT1N+/cT2-T3,X any cN, cM0,X) selected from the Netherlands Cancer Registry (N = 5,824), and how it impacts survival in these patients. Observations revealed an increase in the percentage of patients treated with perioperative treatment from 3% in 2006 to 26% in 2014 and a decrease in the use of only surgery from 60% to 26%. This population-based study indicated no perioperative treatment in a significant share of patients. As per Cox regression analysis, patients who underwent perioperative treatment had better overall survival vs patients who underwent preoperative treatment only; patients who had preoperative chemotherapy vs surgery alone were comparable in terms of survival.